IOncology

The "Northern Breast Cancer Salon Annual Progress Review" was held from January 3–5, 2025, in Beijing. The conference comprehensively reviewed the latest advances in breast cancer diagnosis, treatment, and research over the past year, delving into the latest findings for various breast cancer subtypes and their impact on clinical practice. The conference also focused on discussions regarding updates to the CSCO BC guidelines, providing scientific guidance for clinical practice in breast cancer. At the event, Oncology Frontier invited Dr. Kun Wang from Guangdong Provincial People's Hospital to review the past year’s advancements in the field of early triple-negative breast cancer (TNBC) treatment.

Editor’s Note: With the continuous advancement of medical research, the field of treatment for advanced triple-negative breast cancer (TNBC) is experiencing unprecedented transformation. During the recently held "Northern Breast Cancer…

With the ongoing advancements in breast cancer research, BRCA gene mutations, as a significant genetic risk factor for breast cancer, have attracted increasing attention. In this article, Dr. Songqing Ye from Fujian Provincial Hospital will provide a detailed discussion on the prognosis and treatment advances for BRCA-mutated breast cancer patients, covering the association between BRCA genes and breast cancer, the impact of genetic mutations on prognosis, treatment options, and a comprehensive review of the latest clinical research findings.

Editor's Note: At the end of 2024, the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the "New Little Red Book") was…

Editor’s Note: The Healthy China 2030 plan outlines a shift from a disease-centered approach to a health-centered development model, with a goal of increasing the five-year cancer survival rate by…

Editorial Note: The year 2024 has been a “harvest year” for original research in breast cancer in China, with numerous studies presented at international oncology conferences or published in top-tier…

The global multicenter, randomized, double-blind phase III RATIONALE-305 trial, led by Professor Ruihua Xu as the Global Leading PI, demonstrated that tislelizumab combined with chemotherapy significantly improves overall survival (OS) compared to placebo plus chemotherapy in patients with advanced gastric cancer. This study offers a new first-line treatment option for patients with advanced gastric cancer. At the 2024 European Society for Medical Oncology Asia Congress (ESMO ASIA 2024), the analysis of patient-reported outcomes (PROs) for Asian participants was presented. Oncology Frontier spoke with Dr. Ken Kato from the National Cancer Center Hospital in Japan for his insights.

Pancreatic cancer, often called the “king of cancers,” remains a formidable disease with poor patient outcomes. Challenges stem from the complexity and invasiveness of surgical procedures and limited progress in systemic therapies, which are still largely chemotherapy-based. However, 2024 brought new developments in pancreatic minimally invasive surgery and innovative treatment strategies. In an interview with Oncology Frontier, Dr. Xianjun Yu from Fudan University Shanghai Cancer Center shared his perspective on these advancements, highlighting the refinement of surgical techniques and the emergence of precision medicine approaches for pancreatic cancer.

Editor's Note: The emergence of targeted therapy has ushered in an era of precision medicine for non-small cell lung cancer (NSCLC), leveraging specific targets on tumor cells to block growth…

Editor’s Note: At the 2024 European Society for Medical Oncology (ESMO) Asia Annual Meeting, nine TiP abstracts focused on colorectal cancer from China were presented. Previously, we summarized four of…